A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.
A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.
复制标题
一线治疗失败以及亚洲和南部非洲的一线小儿抗逆转录病毒通行与使用的一线治疗失败以及二线病毒的访问和审查。
DOI：
10.1186/1758-2652-14-7
复制
发表时间：
2011-02-09
影响因子：
6
通讯作者：
International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group
中科院分区：
文献类型：
--
作者：
TREAT Asia Pediatric HIV Observational Database (TApHOD);International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group
为了更好地了解儿科二线抗逆转录病毒疗法(ART)的需求，在治疗亚洲儿科艾滋病毒观察数据库和IeDEA南部非洲(评估艾滋病的国际流行病学数据库)区域队列中进行了ART管理调查和二线ART使用的横断面分析。2009年4月进行了调查。来自亚洲队列的分析数据于2009年3月从柬埔寨、印度、印度尼西亚、马来西亚和泰国的12个中心收集。来自IeDEA南部非洲队列的数据于2008年2月来自马拉维、莫桑比克、南非和津巴布韦的10个中心。调查答复反映了区域间在药物获取和国家准则方面的差异。治疗亚洲组的1301名儿童和南部非洲IeDEA队列中的4561名儿童符合横断面分析的纳入标准。在数据传输时，10%的亚洲儿童和3.3%的非洲儿童正在接受二线抗逆转录病毒治疗。二线启动时的平均年龄(四分位数范围)在亚洲队列中为120(78-145)个月，在南部非洲队列中为66(29-112)个月。治疗方案多种多样，当时世界卫生组织推荐的核苷逆转录酶阿巴卡韦和二磷酸核苷的组合在每个地区只有不到5%的儿童使用。为了向儿童提供终身艺术，需要更好地利用目前的一线疗法和更广泛地获得耐热的儿科二线和抢救配方。除非提供者和患者能够获得适当的药物供儿童改用，否则早期诊断治疗失败的好处将是有限的。
To better understand the need for paediatric second-line antiretroviral therapy (ART), an ART management survey and a cross-sectional analysis of second-line ART use were conducted in the TREAT Asia Paediatric HIV Observational Database and the IeDEA Southern Africa (International Epidemiologic Databases to Evaluate AIDS) regional cohorts. Surveys were conducted in April 2009. Analysis data from the Asia cohort were collected in March 2009 from 12 centres in Cambodia, India, Indonesia, Malaysia, and Thailand. Data from the IeDEA Southern Africa cohort were finalized in February 2008 from 10 centres in Malawi, Mozambique, South Africa and Zimbabwe. Survey responses reflected inter-regional variations in drug access and national guidelines. A total of 1301 children in the TREAT Asia and 4561 children in the IeDEA Southern Africa cohorts met inclusion criteria for the cross-sectional analysis. Ten percent of Asian and 3.3% of African children were on second-line ART at the time of data transfer. Median age (interquartile range) in months at second-line initiation was 120 (78-145) months in the Asian cohort and 66 (29-112) months in the southern African cohort. Regimens varied, and the then current World Health Organization-recommended nucleoside reverse transcriptase combination of abacavir and didanosine was used in less than 5% of children in each region. In order to provide life-long ART for children, better use of current first-line regimens and broader access to heat-stable, paediatric second-line and salvage formulations are needed. There will be limited benefit to earlier diagnosis of treatment failure unless providers and patients have access to appropriate drugs for children to switch to.
登录
查看更多内容
DOI：
10.1097/qai.0b013e31814278c0
发表时间：
2007-10-01
影响因子：
3.6
作者：
Kamya, Moses R.;Mayanja-Kizza, Harriet;Kekitiinwa, Adeodata
通讯作者：
Kekitiinwa, Adeodata
影响因子：
2
作者：
Kumarasamy, N.;Venkatesh, Kartik K.;Solomon, Suniti
通讯作者：
Solomon, Suniti
DOI：
10.2217/hiv.09.28
发表时间：
2009-09-01
期刊：
HIV Therapy
影响因子：
--
作者：
Sohn, Annette H.;Ananworanich, Jintanat
通讯作者：
Ananworanich, Jintanat
影响因子：
3.6
作者：
Puthanakit, Thanyawee;Aurpibul, Linda;Sirisanthana, Virat
通讯作者：
Sirisanthana, Virat
影响因子：
3.6
作者：
Jaspan, Heather B.;Berrisford, Alison E.;Boulle, Andrew M.
通讯作者：
Boulle, Andrew M.